Literature DB >> 33557040

Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis.

Dong Wook Kim1, Sang Hyun Choi1, Ji Sung Lee2, So Yeon Kim1, So Jung Lee1, Jae Ho Byun1.   

Abstract

BACKGROUND: For a proper management strategy in patients with locoregionally treated hepatocellular carcinoma (HCC), it is essential that the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) has high interreader reliability. We aimed to systematically evaluate the interreader reliability of LR-TR and sources of any study heterogeneity.
METHODS: Original studies reporting the interreader reliability of LR-TR were identified in MEDLINE and EMBASE up to 20 September 2020. The pooled kappa coefficient (κ) was calculated using the DerSimonian-Laird random effects model. Subgroup analyses were performed according to imaging modality (magnetic resonance imaging (MRI) or computed tomography (CT)). Meta-regression analyses were performed to explore study heterogeneity.
RESULTS: Eight studies with 851 HCCs were finally included. Pooled κ was 0.70 (95% CI, 0.58-0.82) for CT/MRI LR-TR, and those of MRI and CT were 0.71 (95% CI, 0.53-0.89) and 0.71 (95% CI, 0.65-0.78), respectively. Study design (p < 0.001) and type of treatment (p = 0.02) were significantly associated with substantial study heterogeneity.
CONCLUSION: LR-TR showed substantial interreader reliability regardless of the imaging modality. Because of substantial study heterogeneity, which was significantly associated with study design and type of treatment, published values for the interreader reliability of LR-TR should be interpreted with care.

Entities:  

Keywords:  LI-RADS; computed tomography; hepatocellular carcinoma; interreader reliability; liver; magnetic resonance imaging; meta-analysis; systematic review; treatment response

Year:  2021        PMID: 33557040      PMCID: PMC7913820          DOI: 10.3390/diagnostics11020237

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  33 in total

1.  Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.

Authors:  Jung-Hee Yoon; Eun-Joo Lee; Seong-Sook Cha; Sang-Suk Han; Suk-Jin Choi; Jae-Ryang Juhn; Myung-Hee Kim; Yeon-Jae Lee; Seong-Jae Park
Journal:  J Vasc Interv Radiol       Date:  2010-02-08       Impact factor: 3.464

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

3.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

4.  LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.

Authors:  Se Woo Kim; Ijin Joo; Hyo-Cheol Kim; Su Joa Ahn; Hyo-Jin Kang; Sun Kyung Jeon; Jeong Min Lee
Journal:  Eur Radiol       Date:  2020-01-31       Impact factor: 5.315

5.  Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.

Authors:  David S K Lu; Nam C Yu; Steven S Raman; Charles Lassman; Myron J Tong; Carolyn Britten; Francisco Durazo; Sammy Saab; Steven Han; Richard Finn; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

6.  Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.

Authors:  Nieun Seo; Myoung Soo Kim; Mi-Suk Park; Jin-Young Choi; Richard K G Do; Kyunghwa Han; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2019-08-15       Impact factor: 5.315

7.  Completeness of treatment in hepatocellular carcinomas treated with image-guided tumor therapies: Evaluation of positive predictive value of contrast-enhanced CT with histopathologic correlation in the explanted liver specimen.

Authors:  Young-sun Kim; Hyunchul Rhim; Hyo K Lim; Cheol Keun Park; Won Jae Lee; Young Soo Do; Jae Won Cho
Journal:  J Comput Assist Tomogr       Date:  2006 Jul-Aug       Impact factor: 1.826

8.  Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.

Authors:  Sungeun Park; Ijin Joo; Dong Ho Lee; Jae Seok Bae; Jeongin Yoo; Se Woo Kim; Jeong Min Lee
Journal:  Radiology       Date:  2020-07-21       Impact factor: 11.105

9.  Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation.

Authors:  Stephen J Hunt; Woojin Yu; Joshua Weintraub; Martin R Prince; Nishita Kothary
Journal:  J Vasc Interv Radiol       Date:  2008-11-22       Impact factor: 3.464

10.  LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.

Authors:  Erin L Shropshire; Mohammad Chaudhry; Chad M Miller; Brian C Allen; Erol Bozdogan; Diana M Cardona; Lindsay Y King; Gemini L Janas; Richard K Do; Charles Y Kim; James Ronald; Mustafa R Bashir
Journal:  Radiology       Date:  2019-04-30       Impact factor: 29.146

View more
  1 in total

1.  Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.

Authors:  Krzysztof Bartnik; Joanna Podgórska; Grzegorz Rosiak; Krzysztof Korzeniowski; Olgierd Rowiński
Journal:  Abdom Radiol (NY)       Date:  2021-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.